WFDC2 and endometrial cancer: In 2013, Jiang et al. [60] demonstrated for the first time the differential expression of five HE4 mRNA variants (i.e., V0, V1, V2, V3, and V4) in 16 healthy endometrial samples and 43 endometrial cancer tissues (14 endometrioid G1, 14 endometrioid G3 and 15 papillary serous) to establish an HE4 variant-specific correlation with survival.